Literature DB >> 8977414

Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function.

Y Tajiri1, C Möller, V Grill.   

Abstract

Chronic hyperglycemia has adverse effects on B cell function. We investigated the possible role of advanced glycosylation end products (AGEs) in glucotoxicity. Rat islets were cultured at different glucose concentrations for 1-6 weeks in RPMI 1640. Culture was performed with or without aminoguanidine (AG), which is known to prevent AGE formation in other tissues. AGE-associated fluorescence (370 nm excitation and 440 nm emission) progressively increased during 6 weeks of culture at 38 nM, but not at 11 or 5.5 mM, glucose. The increase in fluorescence was significantly inhibited by AG. The effects of AG on insulin secretion were tested directly after the culture period as well as after a wash-out period of continued culture at 11 mM glucose in the absence of AG. The presence of AG during culture for 1 week at 38 mM glucose failed to affect basal release at 3.3 mM glucose or stimulated release at 27 mM glucose. AG was ineffective whether tested directly after the culture period or after wash-out. When the same culture conditions were prolonged for 6 weeks, culture with AG suppressed basal and stimulated insulin secretion after the culture period. However, after wash-out, previous AG treatment enhanced the insulin response to 27 mM glucose 2-fold compared to culture without AG (P < 0.01). Proinsulin and total protein biosyntheses in 38 mM glucose-cultured islets were increased 40-80% by AG after 6 weeks of culture, and this effect was similar after wash-out. Preproinsulin messenger RNA levels were significantly increased (P < 0.05) after 6 weeks of culture with AG. NG-Methyl-L-arginine, a nitric oxide synthase inhibitor, failed to mimic the effects of AG. The results indicate that the time-dependent beneficial effects of AG on insulin secretion and biosynthesis are related to inhibitory effects on AGE formation and that accumulation of islet AGEs could be important for glucotoxicity toward B cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8977414     DOI: 10.1210/endo.138.1.4851

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  28 in total

Review 1.  Glucolipotoxicity: fuel excess and beta-cell dysfunction.

Authors:  Vincent Poitout; R Paul Robertson
Journal:  Endocr Rev       Date:  2007-11-29       Impact factor: 19.871

2.  Spotlight on ethnomedicine: usability of Sutherlandia frutescens in the treatment of diabetes.

Authors:  Charles Sia
Journal:  Rev Diabet Stud       Date:  2004-11-10

3.  Increased expression of cyclooxygenase-2 in human pancreatic islets treated with high glucose or ligands of the advanced glycation endproduct-specific receptor (AGER), and in islets from diabetic mice.

Authors:  N Shanmugam; I T Todorov; I Nair; K Omori; M A Reddy; R Natarajan
Journal:  Diabetologia       Date:  2005-12-10       Impact factor: 10.122

4.  Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.

Authors:  K Arakawa; T Ishihara; A Oku; M Nawano; K Ueta; K Kitamura; M Matsumoto; A Saito
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 5.  Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.

Authors:  Surapon Tangvarasittichai
Journal:  World J Diabetes       Date:  2015-04-15

6.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Frédéric Ris; José Oberholzer; Helen I Joller-Jemelka; Giatgen A Spinas; Nurit Kaiser; Philippe A Halban; Marc Y Donath
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 7.  Advanced-glycation end products in insulin-resistant states.

Authors:  Georgia Soldatos; Mark E Cooper; Karin A M Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

8.  In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs.

Authors:  Angela Cassese; Iolanda Esposito; Francesca Fiory; Alessia P M Barbagallo; Flora Paturzo; Paola Mirra; Luca Ulianich; Ferdinando Giacco; Claudia Iadicicco; Angela Lombardi; Francesco Oriente; Emmanuel Van Obberghen; Francesco Beguinot; Pietro Formisano; Claudia Miele
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

9.  Accelerated loss of islet beta cells in sucrose-fed Goto-Kakizaki rats, a genetic model of non-insulin-dependent diabetes mellitus.

Authors:  M Koyama; R Wada; H Sakuraba; H Mizukami; S Yagihashi
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

Review 10.  Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

Authors:  Helen Vlassara; Jaime Uribarri
Journal:  Curr Diab Rep       Date:  2014-01       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.